<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112199</url>
  </required_header>
  <id_info>
    <org_study_id>CIT-002</org_study_id>
    <nct_id>NCT04112199</nct_id>
  </id_info>
  <brief_title>A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites</brief_title>
  <official_title>A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioVie Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioVie Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion&#xD;
      in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of&#xD;
      ascites and complications in adult patients with refractory ascites secondary to&#xD;
      decompensated cirrhosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Terlipressin has been shown to reduce portal hypertension, improve renal function and induce&#xD;
      natriuresis in cirrhotic patients with ascites without hepatorenal syndrome (HRS). It is&#xD;
      approved in Europe for the treatment of bleeding esophageal varices and HRS type 1 and is&#xD;
      usually administered as an IV bolus starting at 1 mg every 6 h and increased to 2 mg every 6&#xD;
      h (maximum 8 mg/day depending on response).&#xD;
&#xD;
      This study will evaluate the use of terlipressin delivered by continuous infusion for two 28&#xD;
      day treatment cycles for reduction of ascites accumulation and complications in adult&#xD;
      patients with refractory ascites secondary to decompensated cirrhosis. Continuous infusion&#xD;
      allows for a significant reduction in the daily effective dose required for treatment and&#xD;
      improved safety of terlipressin delivered as a low-dose continuous infusion could enable its&#xD;
      use in the outpatient setting in the prolonged treatment of patients with refractory ascites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Thirty patients will be randomized to either BIV201 continuous infusion plus SOC or SOC alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complications, at least grade 2 severity</measure>
    <time_frame>180 days following randomization</time_frame>
    <description>Incidence of complications, at least grade 2, during the 180 days following randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cumulative ascites</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in cumulative ascites during the first 12 weeks following randomization versus the 12 weeks pre-treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ascites</condition>
  <condition>Decompensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>BIV201 plus Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIV201 continuous infusion - treatment for two 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Per AASLD guidelines: diuretics and therapeutic paracentesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIV201 continuous infusion</intervention_name>
    <description>BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.</description>
    <arm_group_label>BIV201 plus Standard of Care</arm_group_label>
    <other_name>terlipressin diacetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Informed consent prior to any study-related procedures&#xD;
&#xD;
          -  Male or female patients age 18 to 75 years old&#xD;
&#xD;
          -  Cirrhosis of the liver (Non-alcoholic steatohepatitis, alcohol, viral and autoimmune)&#xD;
&#xD;
          -  Patient has diuretic-resistant, intractable ascites or is unsuitable for treatment&#xD;
             with diuretics and required:&#xD;
&#xD;
             o In the 60-day period from the last LVP before consent, required, between 3 and 9&#xD;
             LVPs, including the last LVP on or before the day of consent.&#xD;
&#xD;
          -  Dates for all LVPs that occurred within 90 days prior to consent have been recorded.&#xD;
             The volume of ascites removed at each of the LVPs must also have been recorded for the&#xD;
             90-day period prior to the last LVPs before consent&#xD;
&#xD;
          -  Serum creatinine (SCr) â‰¤2.00 mg/dL determined prior to randomization&#xD;
&#xD;
          -  Women of child-bearing potential (e.g. not post-menopausal for at least one year or&#xD;
             surgically sterile) must be neither pregnant nor lactating and must agree to use&#xD;
             adequate birth control or be abstinent for the duration of the study&#xD;
&#xD;
          -  If patient is treated with ACE inhibitors or beta blockers, dose has been stable for&#xD;
             at least 30 days prior to randomization and may be maintained on that dose for the&#xD;
             trial duration&#xD;
&#xD;
          -  If patient is treated with diuretics, patient has been on a stable daily dose for at&#xD;
             least 10 days prior to consent&#xD;
&#xD;
          -  Willing and able to comply with trial instructions&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Ascites with causes other than cirrhosis; such as cardiac or nephrogenic ascites or&#xD;
             malignant ascites due to peritoneal carcinomatosis&#xD;
&#xD;
          -  Urinary sodium excretion &gt;100 mmol/day between day of consent and randomization&#xD;
&#xD;
          -  Total bilirubin &gt;5 mg/dL&#xD;
&#xD;
          -  Blood clotting International normalized ratio (INR) &gt;2.5&#xD;
&#xD;
          -  Current or recent (within 3 months of consent) renal replacement therapy&#xD;
&#xD;
          -  Current or recent (within 3 month of consent) hepatic encephalopathy Grade 3 or 4&#xD;
             (West-Haven)&#xD;
&#xD;
          -  Superimposed acute liver failure/injury due to factors including acute alcoholic&#xD;
             hepatitis, acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other&#xD;
             toxins (e.g., mushroom [Amanita] poisoning)&#xD;
&#xD;
          -  History or presence of hepatic hydrothorax, known pulmonary hypertension and a history&#xD;
             of hepatopulmonary syndrome&#xD;
&#xD;
          -  Current or recent treatment (within 7 days of randomization) with octreotide,&#xD;
             midodrine, vasopressin, dopamine or other vasopressors&#xD;
&#xD;
          -  Current or recent (in the previous 60 days from consent) episode of respiratory&#xD;
             failure requiring positive airway pressure (PAP) devices or intubation&#xD;
&#xD;
          -  Sepsis episode in the previous 28 days from consent&#xD;
&#xD;
          -  Episode of SBP within the 28 days prior to consent&#xD;
&#xD;
          -  Episode of gastrointestinal hemorrhage (non-variceal) within 28 days prior to consent&#xD;
&#xD;
          -  Episode of esophageal variceal bleed within one week prior to consent&#xD;
&#xD;
          -  Ongoing documented or suspected infection&#xD;
&#xD;
          -  Severe cardiovascular disease that is a contraindication to terlipressin therapy such&#xD;
             as a history of myocardial infarction, angina pectoris, advanced arteriosclerosis,&#xD;
             uncontrolled cardiac arrhythmia, severe coronary insufficiency or uncontrolled&#xD;
             hypertension&#xD;
&#xD;
          -  Findings suggestive of severe organic renal disease (severe proteinuria/hematuria, or&#xD;
             abnormal renal ultrasound suggestive of obstructive renal pathology)&#xD;
&#xD;
          -  Use of nephrotoxic drugs (e.g., aminoglycosides) in the 4 weeks before screening&#xD;
&#xD;
          -  Severe comorbidity that in the opinion of the Investigator would affect short-term&#xD;
             prognosis and/or disallow safe participation in the trial (such as for example, severe&#xD;
             anemia or pancytopenia, advanced progressive neoplasia such as hepatocellular&#xD;
             carcinoma, unless eligible for transplant)&#xD;
&#xD;
          -  Patient who, in the judgment of the investigator, has been an excessive alcohol&#xD;
             drinker in the past 12 weeks&#xD;
&#xD;
          -  Patient is in the opinion of the investigator, despite previous education on sodium&#xD;
             restriction, anticipated to remain grossly non-compliant of sodium restricted diet&#xD;
&#xD;
          -  Implanted alfapump or previous recipient of alfapump that had pump removed within past&#xD;
             3 months&#xD;
&#xD;
          -  Recipient of renal or liver transplant&#xD;
&#xD;
          -  Planned elective surgery related to cirrhosis complications, for example for hernia&#xD;
             repair&#xD;
&#xD;
          -  Known allergy or hypersensitivity to terlipressin&#xD;
&#xD;
          -  Participation in other clinical research studies involving the treatment with other&#xD;
             investigational drugs or evaluation with implantable devices within 30 days of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giacomo Basadonna, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioVie Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Penelope Markham, PhD</last_name>
    <phone>7035989972</phone>
    <email>pmarkham@biovieinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan M Adams</last_name>
    <phone>3123265971</phone>
    <email>jadams@biovieinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Landon</last_name>
      <phone>310-825-7876</phone>
      <email>clandon@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sammy Saab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Brannock</last_name>
      <phone>904-953-4133</phone>
      <email>Brannock.robert@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Keaveney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Olson</last_name>
      <phone>305-243-6939</phone>
      <email>malourdes@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sonia Carvalho</last_name>
      <phone>3052434639</phone>
      <email>scarvalho@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mijares</last_name>
      <phone>305-243-6405</phone>
      <email>mmijares74@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Olofson</last_name>
      <phone>507-538-6547</phone>
      <email>olofson.amy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Simonetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Calvin Trisolini</last_name>
      <phone>215-615-3755</phone>
      <email>calvin.trisolini@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Rajender Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ethan Weinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Conley</last_name>
      <phone>843-876-4273</phone>
      <email>conleyc@musc.edu</email>
    </contact>
    <investigator>
      <last_name>David Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Campbell</last_name>
      <phone>615-343-5683</phone>
      <email>Kathryn.Campbell@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Porayko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire Veterans Affairs Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edie Gavis, RN</last_name>
      <email>edie.gavis@va.gov</email>
    </contact>
    <investigator>
      <last_name>Jasmohan Bajaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Terlipressin</keyword>
  <keyword>Refractory ascites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified individual participant data for primary and secondary end-points may be made available after NDA filing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

